Showing 2851-2860 of 9134 results for "".
Finding Joy in Dermatology
https://practicaldermatology.com/issues/october-2025/finding-joy-in-dermatology/39751/Go out there and find your joy. Do more of it. And appreciate every second of it.Global Aesthetics and Regenerative Medicine
https://practicaldermatology.com/issues/october-2025/global-aesthetics-and-regenerative-medicine/39760/Global aesthetics and regenerative medicine are growing fields that integrate regenerative therapies into aesthetic treatments to improve and restore tissues affected by aging or damage.Damn The Torpedoes…Full Speed Backwards
https://practicaldermatology.com/series/editors-message/damn-the-torpedoesfull-speed-backwards/24207/At the Battle of Mobile Bay…warned of mines (called torpedoes) in the water ahead…Farragut said, “Damn the torpedoes! Captain Drayton, go ahead! Jouett, full speed!”Taking the Leap Into Private Practice
https://practicaldermatology.com/programs/practical-dermatology/taking-the-leap-into-private-practice/24042/Practice is hard. Private practice is even harder.Home-Use Laser and Light Devices: Just What the Doctor Ordered
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/home-use-laser-and-light-devices-just-what-the-doctor-ordered/23335/Laser and light-based devices are more at home than ever as lightweight LEDs, wearable technology, and “smart” apps support adherence and enhance efficacy.Device-Based Approaches to Acne and Rosacea
https://practicaldermatology.com/topics/psoriasis/device-based-approaches-to-acne-and-rosacea/20485/Leading dermatologists share pearls on device-based acne and rosacea treatments.Pay it Backwards
https://practicaldermatology.com/topics/practice-management/pay-it-backwards/20640/Why do women in dermatology earn only 83 percent of what men earn?Dupixent, Juvéderm Vollure XC, Bavencio Approvals
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-dupixent-juv-derm-vollure-xc-bavencio-approvals/18698/The FDA has approved Regeneron's injectable Dupixent (dupilumab) to treat adults with moderate-to-severe eczema. It will be marketed by Regeneron and Sanofi Genzyme in the US. Allergan's Juvéderm Vollure XC has received FDA approval based on a pivotal clinical trial in which 59 percent of subjects sBody Dysmorphic Disorder Screening Tools for the Dermatologist: A Systematic Review
https://practicaldermatology.com/topics/general-topics/body-dysmorphic-disorder-screening-tools-for-the-dermatologist-a-systematic-review-s/21231/Beware the Redheaded Patient: Fact or Fiction in Cosmetic and Surgical Dermatology?
https://practicaldermatology.com/topics/general-topics/beware-the-redheaded-patient-fact-or-fiction-in-cosmetic-and-surgical-dermatology/21417/One of the winning presentations given by dermatology residents at the Cosmetic Surgery Forum in December 2013.